CUE

CUE

USD

Cue Biopharma Inc. Common Stock

$0.639+0.011 (1.752%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$0.628

Máximo

$0.660

Mínimo

$0.620

Volumen

0.10M

Fundamentos de la Empresa

Capitalización de Mercado

48.1M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.16M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $0.45Actual $0.639Máximo $1.989

Noticias Relacionadas

GlobeNewswire

Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference

BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

Ver más
Cue Biopharma to Participate in Fireside Chat at the Citizens Life Sciences Conference
GlobeNewswire

Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

Ver más
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
GlobeNewswire

Cue Biopharma to Host Business Update Call and Webcast

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

Ver más
Cue Biopharma to Host Business Update Call and Webcast
GlobeNewswire

Cue Biopharma Announces Proposed Public Offering

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate

Ver más
Cue Biopharma Announces Proposed Public Offering
GlobeNewswire

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Partnership bolsters Boehringer's autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need.The agreement focuses on further research and development of a novel,

Ver más
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.